Compare Synchrony Financial (SYF) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synchrony Financial vs Travere Therapeutics Inc. Common Stock — how do they compare? Synchrony Financial trades at $71.41 (market cap $23.94B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Synchrony Financial is far larger — about 4.9× Travere Therapeutics Inc. Common Stock's market cap, and Synchrony Financial pays a 1.85% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Synchrony Financial for 30 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SYF | TVTX | |
|---|---|---|
Market Cap | $23.94B | $4.88B |
Volume | 2,618,932 | 1,668,577 |
Sector | Financials | Health |
52-Week High | $88.47 | $67.52 |
52-Week Low | $63.78 | $26.79 |
Typical Hold Time | 30 Days | 0 Days |
Enterprise Value | $24.18B | $5.01B |
Dividend Yield | 1.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synchrony Financial (SYF) trades at $73.59, down slightly by 0.04% on the day. The stock exhibits a bullish technical signal overall, with support near $73 and resistance at $75. Fundamentally, the company shows strong profitability with a 23.4% net income margin and a compelling valuation at a P/E of 7.55. Recent earnings have consistently beaten expectations, and strategic partnerships, like the one with OpenAI announced on August 17, 2026, highlight growth initiatives.
The outlook for SYF is positive, supported by robust analyst sentiment with a consensus price target of $87.50, implying significant upside. Key opportunities include high ROE and strategic expansions in digital finance. Risks involve potential consumer credit deterioration, as noted in broader market news on August 26, 2026, and increased investing cash outflows in 2026, which could pressure near-term liquidity.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
